PCSK9 inhibitors shine at AHA, but how to differentiate?
This article was originally published in Scrip
Executive Summary
Phase III results for the PCSK9 inhibitor alirocumab from Regeneron Pharmaceuticals and partner Sanofi and their competitor Amgen's evolocumab show remarkable reductions in LDL-cholesterol (LDL-c) levels, but the similar body of data for both biologics make it difficult to guess which therapy will come out on top as they edge closer to US FDA approval in 2015.